Welcome to our dedicated page for MAIA Biotechnology SEC filings (Ticker: MAIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MAIA Biotechnology, Inc. filings document the regulatory record for a clinical-stage oncology company developing ateganosine for non-small cell lung cancer. Form 8-K reports cover THIO-101 clinical updates, oncology conference materials, shareholder communications on the development pipeline, FDA Fast Track disclosure, and forward-looking risk language tied to investigational drug development.
The company’s filings also document capital structure and governance matters, including an underwritten common stock offering conducted under an effective Form S-3 shelf registration, the related underwriting agreement and use-of-proceeds disclosure, executive compensation actions, and annual meeting proxy matters such as director elections and auditor ratification.
MAIA Biotechnology (NYSE:MAIA) filed an 8-K disclosing a Stock Purchase Agreement signed 24 Jun 2025 with Prevail Partners.
MAIA will issue up to $587,905 in common shares: a $58,800 upfront block and 36 equal tranches of $14,697. Shares price at 120% of the 30-day VWAP, but not below $1.74; at this floor the maximum issuance is 337,876 shares. A 19.99% ownership blocker prevents Prevail from exceeding that stake. The unregistered sale (Sections 4(a)(2)/3(a)(9)) qualifies as a Material Definitive Agreement (Item 1.01) and Unregistered Sales of Equity Securities (Item 3.02).
Proceeds will pay Prevail Infoworks for technology and services tied to MAIA’s Phase 3 THIO + cemiplimab lung-cancer trial, providing non-cash financing while introducing moderate dilution.
MAIA Biotechnology (NYSE: MAIA) announced the appointment of new members to its Scientific Advisory Board on June 24, 2025. The company, an emerging growth company listed on NYSE American, filed this 8-K to disclose the board expansion.
Key aspects of the filing include:
- The announcement was made through a press release (Exhibit 99.1)
- The company maintains its headquarters at 444 West Lake Street, Chicago
- The filing includes standard forward-looking statements highlighting potential risks in areas such as:
- Clinical study initiation, timing, and results
- Regulatory approval processes
- Product development and manufacturing capabilities
- Market acceptance and commercialization potential
- Intellectual property protection
The document was signed by Vlad Vitoc, Chief Executive Officer of MAIA Biotechnology.